Developed for rheumatoid arthritis to target inflammatory pathways and support joint preservation.
Mechanism of Action
Baricitinib is a selective and reversible Janus kinase (JAK) inhibitor. By blocking the activity of JAK1 and JAK2, it prevents the phosphorylation and activation of signal transducers and activators of transcription (STATs), thereby reducing cytokine-mediated inflammation.
Route of Administration
Oral
Onset Time
1–4 weeks
Duration
12–24 hours
Contraindications
Pregnancy, Severe renal impairment, Active infection, Hypersensitivity to baricitinib
Severe Adverse Events
Thrombosis, Serious infections, Gastrointestinal perforation — requires immediate medical attention
Information related to Olumiant is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
